Mediquest Therapeutics, Inc.

Other

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Kansas

U.S. Government Nih Division of Extramural Inventions and Technology Resources (deitr)

Oridigm Corporation

Mark R Burns

Donald E Bergstrom

Christine L O'Day

Gerard F Graminski

Nicolaas M J Vermeulin

Heather K Webb

Sunil Abraham David

Maralee McVean

Bruce H Devens

Kevin Kennedy

Arthur Yeung

Nand Baindur

Kyle W Burns

Scott A Jenkins

Reitha S Weeks

The invention relates to covers for wastewater treatment lagoons, which are typically covered by expansive stretches of sheet-form, high density polyethylene (HDPE). The invention more particularly relates to improvements in attaching HDPE patches at distributed locations thereon, which patches provide locally increased thickness to the cover in service as seats for attachment of further attachments to the cover, such as for example and without limitation HDPE straps for retention of HDPE grout-filled ballast pipes, and so on.

HDPE covers for wastewater treatment lagoons, and HDPE patches thereon in service for further attachments

Small molecule polycationic agents are used to modulate or interrupt biological processes by binding to oligosaccharide-based biomolecules. Compounds that inhibit nitric oxide, TNF&#x3b1; or other immunomodulators are provided and are useful for treating immunological disease and disease of an infectious disorder.

Recognition of oligosaccharide molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases

Proliferative cutaneous disease states or conditions are treated by administering a polyamine transport inhibitorR-X-L-polyamine

Composition containing polyamine transport inhibitor and use thereof

Certain lipophilic polycationic sulfonamides are provided and are useful for treating various diseases or conditions and particularly sepsis.

Polycationic sulfonamides and use thereof

The synthesis and use of a novel class of tumor necrosis factor (TNF&#x3b1;) inhibitors and immunomodulators are provided. Examples are those having the structures: wherein a, b and c are integers from 0 to 12, X equals NH or CHNH, Rand Reach is a hydrogen or a Cto Caliphatic; aliphatic amine; an alicyclic; aromatic; heterocycle; and halogenated forms thereof; and 

Immunomodulation with novel pharmaceutical compositions

Tetrahydro-&#x3b2;-carboline compounds represented by the following formulae:  wherein x, y and z are each independently an integer of 0 to 4 and R is selected from the group consisting of H, alkyl, aryl and heterocyclic moiety wherein the alkyl, aryl and heterocyclic moiety are optionally substituted with a member selected from the group consisting of halogen, alkoxy and trifluoromethyl; pharmaceutically acceptable salts thereof and prodrugs thereof are provided. The compounds are useful for treating neurological diseases.

Tetrahydro-&#x3b2;-carboline compounds and use thereof

Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinational polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.

Polyamine analogues as therapeutic and diagnostic agents

Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases

Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinatiorial polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.

Novel polyamines, their synthesis and use in pharmacological, cosmetic or agricultural applications are provided. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by omithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compounds will preferably enter the cell independent of the polyamine transporter. As drugs, these compounds are used to treat any disease associated with cellular proliferation including but not limited to cancer.

Polyamine analogs that activate antizyme frameshifting

The disclosed invention provides new polyamine analogs and derivatives containing a hydrophobic region and a polyamine region as well as methods and compositions for their use.

Hydrophobic polyamine analogs and methods for their use

The synthesis and use of a novel class of tumor necrosis factor (TNF&#x3b1;) inhibitors and immunomodulators are provided. These compounds have pharmacological applications as well as uses in assays relating to TNF&#x3b1; and other involved cytokines. As pharmaceuticals, these compounds are used to treat inflammatory, infectious, autoimmune or other proliferative diseases and conditions related to the unwanted presence or activity of TNF&#x3b1; and/or one or more other involved cytokines, alone or in combination with other agents. Examples of compounds of the present invention are those having the structures as shown below: wherein, a, b and c may be the same or different and are integers from 0 to 12, X equals NH or CHNH, Rand Rcan be the same or different and equal to a hydrogen or a straight or branched Cto Csaturated or unsaturated aliphatic; aliphatic amine; an alicyclic; single or multi-ring aromatic; a single or multi-ring aromatic heterocycle; a single or multi-ring saturated heterocycle and the halogenated forms thereof; and

Novel polyamines, their synthesis and use in pharmacological, cosmetic or agricultural applications are provided. The polyamines induce antizyme production which in turn down regulates both the production of polyamines by ornithine decarboxylase (ODC) and the transport of polyamines by its corresponding polyamine transporter. These compounds will preferably enter the cell independent of the polyamine transporter. As drugs, these compounds are used to treat any disease associated with cellular proliferation including but not limited to cancer.

Cytotoxic polyamine analogues are provided that are useful for treating diseases where it is desired to inhibit cell growth and/or proliferation, for example cancer and post-angioplasty injury.

Polyamine analogues as cytotoxic agents

Novel &ldquo;bispolyamine&rdquo; inhibitor compounds of polyamine transport are disclosed. These compounds are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. These compounds display desirable activities both for diagnostic and research assays and therapy.

Growing community of inventors

Shoreline, WA, United States of America

Mark R Burns